Genetic
rAAV2-ND4
rAAV2-ND4 is a genetic therapy with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
1
25%
Ph not_applicable
2
50%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Other(2)
Detailed Status
unknown2
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (25.0%)
Phase 31 (25.0%)
N/A2 (50.0%)
Trials by Status
unknown250%
active_not_recruiting125%
completed125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_3
A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation
NCT07406854
unknownphase_2
A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy
NCT03153293
unknownnot_applicable
Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months
NCT03428178
completednot_applicable
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
NCT01267422
Clinical Trials (4)
Showing 4 of 4 trials
NCT07406854Phase 3
A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation
NCT03153293Phase 2
A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy
NCT03428178Not Applicable
Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months
NCT01267422Not Applicable
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
All 4 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 4